Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CART) Therapy Directed Against BCMA and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma.

NCT07391657 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07391657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07391657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CART) Therapy Directed Against BCMA and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma.
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Recruiting
Start date
February 23, 2026
Completion date
July 29, 2030
Enrollment
508 (estimated)
Sites
143

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed refractory multiple myeloma